Drug Profile
Research programme: cancer immunotherapy - Tessa Therapeutics/Parker Institute for Cancer Immunotherapy
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Parker Institute for Cancer Immunotherapy; Tessa Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 19 Jun 2017 Early research in Cancer in USA (Parenteral)
- 19 Jun 2017 Tessa Therapeutics and the Parker Institute for Cancer Immunotherapy signed an agreement for development of cancer immunotherapy